Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05883371 · ClinicalTrials.gov registry record
IMPACT - AndHealth Autoimmune Research Registry
A clinical trial of Psoriasis and Arthritis, Rheumatoid, sponsored by AndHealth.
- Recruiting
- Registry status
- 2,500
- Enrollment target
- 1
- Study location
NCT05883371: Recruiting study of Psoriasis and Arthritis, Rheumatoid, sponsored by AndHealth.
NCT05883371 is a study of Psoriasis and Arthritis, Rheumatoid that is actively recruiting participants, run by AndHealth. The registered enrollment target is 2,500 participants, above the 469-participant average among 125 other Psoriasis trials with a reported enrollment target (433% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05883371, a study of Psoriasis and Arthritis, Rheumatoid, is actively recruiting participants, sponsored by AndHealth.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach ("AndHealth program") for autoimmune disorders. This approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed physician with the support of health coaches. While protocol guidance is provided, the therapeutic approach is personalized to the individual needs of patients. The autoimmune disorders of focus in this registry include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. A variety of validated labs, patient-reported outcomes, and medication usage will be assessed among participating patients over a period of up to five years to evaluate the long-term effectiveness of this approach.
Primary Outcome
Change in PROMIS - Global Health is a co-primary outcome for all patients. All patients will provide the PROMIS - Global Health at baseline and all follow-up visits. The 10-item PROMIS Global Health is a patient-reported survey that was designed for use in complex heterogeneous patient populations. The PROMIS Global Health measures overall health status across several physical and mental health areas. PROMIS t-scores range from 16.2 to 67.7 (Physical Health) and 21.2 to 67.6 (Mental Health) with
Conditions Studied
Interventions
- OTHER Root-cause autoimmune treatment program
Study Locations (1)
Ohio
- AndHealth - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2028-05-22 |
What NCT05883371 shows while recruiting
NCT05883371 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 469-participant average among 125 other Psoriasis trials with a reported enrollment target (433% higher).
The record links to 5 conditions, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Root-cause autoimmune treatment program is the first listed.
NCT05883371 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05883371 about?
NCT05883371 is a clinical study titled "IMPACT - AndHealth Autoimmune Research Registry". This is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach ("AndHealth program") for autoimmune disorders. This approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed phy...
What is the current status of trial NCT05883371?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2023-06-08. Estimated completion is 2028-05-22.
What conditions does trial NCT05883371 study?
This clinical trial studies the following conditions: Psoriasis, Arthritis, Rheumatoid, Autoimmune Diseases, Arthritis, Psoriatic, Ankylosing Spondylitis.
What interventions are being tested in trial NCT05883371?
The interventions under investigation include: Root-cause autoimmune treatment program (OTHER).
Who is sponsoring clinical trial NCT05883371?
This trial is sponsored by AndHealth, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05883371 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05883371's enrollment target sits among peer trials
2,500 3rd of 125 higher than 123 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI